Trial Profile
The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Tesamorelin (Primary)
- Indications Mild cognitive impairment
- Focus Therapeutic Use
- 01 Nov 2019 Status changed from recruiting to completed.
- 16 Apr 2019 Planned End Date changed from 1 Sep 2019 to 1 Dec 2019.
- 16 Apr 2019 Planned primary completion date changed from 1 Sep 2019 to 1 Dec 2019.